Anita Katharina Wagner, D.P.H., Dr.Pharm.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drug Approval | 4 | 2023 | 816 | 1.560 |
Why?
|
| Drug Costs | 8 | 2021 | 1185 | 1.330 |
Why?
|
| United States Food and Drug Administration | 4 | 2023 | 1677 | 0.950 |
Why?
|
| Health Expenditures | 7 | 2024 | 2362 | 0.920 |
Why?
|
| Drugs, Essential | 5 | 2021 | 70 | 0.900 |
Why?
|
| Prescription Drugs | 3 | 2020 | 630 | 0.790 |
Why?
|
| Insurance, Health | 5 | 2020 | 2501 | 0.660 |
Why?
|
| Pharmaceutical Preparations | 4 | 2020 | 1091 | 0.640 |
Why?
|
| Insurance Coverage | 6 | 2020 | 1939 | 0.620 |
Why?
|
| Muscular Atrophy, Spinal | 1 | 2020 | 258 | 0.570 |
Why?
|
| Health Surveys | 5 | 2013 | 4063 | 0.560 |
Why?
|
| Health Services Accessibility | 7 | 2018 | 5397 | 0.520 |
Why?
|
| Reimbursement Mechanisms | 3 | 2020 | 664 | 0.510 |
Why?
|
| Neoplasms | 8 | 2022 | 22075 | 0.510 |
Why?
|
| Decision Making | 2 | 2020 | 3925 | 0.480 |
Why?
|
| Benzodiazepines | 3 | 2007 | 1131 | 0.480 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2017 | 385 | 0.460 |
Why?
|
| Deductibles and Coinsurance | 4 | 2018 | 316 | 0.460 |
Why?
|
| Cost of Illness | 3 | 2013 | 1940 | 0.440 |
Why?
|
| Financing, Personal | 2 | 2013 | 309 | 0.440 |
Why?
|
| Medication Therapy Management | 1 | 2014 | 132 | 0.440 |
Why?
|
| National Health Programs | 2 | 2015 | 441 | 0.410 |
Why?
|
| Health Policy | 4 | 2017 | 2677 | 0.390 |
Why?
|
| Quality Control | 1 | 2014 | 828 | 0.390 |
Why?
|
| Breast Neoplasms | 7 | 2022 | 21029 | 0.370 |
Why?
|
| Quality Assurance, Health Care | 2 | 2018 | 2176 | 0.350 |
Why?
|
| Commerce | 1 | 2015 | 605 | 0.350 |
Why?
|
| Antineoplastic Agents | 3 | 2021 | 13627 | 0.340 |
Why?
|
| Quality of Health Care | 5 | 2018 | 4360 | 0.330 |
Why?
|
| Hepatitis C, Chronic | 1 | 2017 | 1031 | 0.330 |
Why?
|
| Medicare | 3 | 2022 | 6785 | 0.330 |
Why?
|
| Drug Industry | 1 | 2015 | 789 | 0.320 |
Why?
|
| Translating | 3 | 1999 | 148 | 0.320 |
Why?
|
| Terminal Care | 1 | 2020 | 1758 | 0.310 |
Why?
|
| New Zealand | 2 | 2020 | 355 | 0.300 |
Why?
|
| Medicaid | 4 | 2017 | 2815 | 0.290 |
Why?
|
| Aromatase Inhibitors | 1 | 2011 | 511 | 0.290 |
Why?
|
| Hip Fractures | 2 | 2007 | 989 | 0.280 |
Why?
|
| Ovarian Neoplasms | 1 | 2024 | 4878 | 0.280 |
Why?
|
| Tamoxifen | 1 | 2011 | 963 | 0.280 |
Why?
|
| Medical Oncology | 1 | 2018 | 2313 | 0.270 |
Why?
|
| Drug Utilization Review | 2 | 2005 | 251 | 0.260 |
Why?
|
| Drug Labeling | 2 | 2006 | 251 | 0.260 |
Why?
|
| Antiviral Agents | 1 | 2017 | 3061 | 0.250 |
Why?
|
| Health Services Needs and Demand | 1 | 2013 | 1399 | 0.240 |
Why?
|
| Legislation, Drug | 1 | 2007 | 214 | 0.240 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2018 | 1529 | 0.230 |
Why?
|
| Anti-Anxiety Agents | 1 | 2007 | 397 | 0.230 |
Why?
|
| Sickness Impact Profile | 2 | 1995 | 298 | 0.230 |
Why?
|
| Drug Prescriptions | 4 | 2010 | 1673 | 0.220 |
Why?
|
| Epilepsy | 6 | 2000 | 3267 | 0.220 |
Why?
|
| Melanoma | 1 | 2022 | 5697 | 0.210 |
Why?
|
| Drug Substitution | 2 | 2018 | 296 | 0.210 |
Why?
|
| Drugs, Generic | 2 | 2018 | 448 | 0.210 |
Why?
|
| Indazoles | 1 | 2024 | 302 | 0.200 |
Why?
|
| Carbapenems | 1 | 2023 | 123 | 0.200 |
Why?
|
| United States | 16 | 2023 | 72448 | 0.200 |
Why?
|
| Hospital Costs | 1 | 2008 | 976 | 0.200 |
Why?
|
| Phthalazines | 1 | 2024 | 382 | 0.190 |
Why?
|
| Health Status | 7 | 2000 | 4082 | 0.190 |
Why?
|
| Humans | 56 | 2024 | 760613 | 0.190 |
Why?
|
| Regression Analysis | 5 | 2016 | 6359 | 0.190 |
Why?
|
| Healthcare Disparities | 2 | 2016 | 3386 | 0.190 |
Why?
|
| Primary Health Care | 1 | 2017 | 4647 | 0.180 |
Why?
|
| Belgium | 1 | 2020 | 118 | 0.180 |
Why?
|
| Medication Adherence | 1 | 2011 | 2165 | 0.170 |
Why?
|
| Drug Therapy | 1 | 2002 | 504 | 0.160 |
Why?
|
| Thailand | 3 | 2016 | 289 | 0.160 |
Why?
|
| Quality of Life | 6 | 2000 | 13308 | 0.160 |
Why?
|
| Developed Countries | 2 | 2017 | 442 | 0.150 |
Why?
|
| Aftercare | 1 | 2003 | 916 | 0.140 |
Why?
|
| Delivery of Health Care | 2 | 2022 | 5325 | 0.140 |
Why?
|
| Health Status Indicators | 3 | 2000 | 968 | 0.140 |
Why?
|
| Sentinel Surveillance | 1 | 2018 | 293 | 0.140 |
Why?
|
| Drug Utilization | 3 | 2015 | 1195 | 0.130 |
Why?
|
| Indoles | 1 | 2024 | 1829 | 0.130 |
Why?
|
| Policy Making | 2 | 2017 | 538 | 0.130 |
Why?
|
| Piperidines | 1 | 2024 | 1650 | 0.130 |
Why?
|
| Aged | 19 | 2024 | 169143 | 0.130 |
Why?
|
| Cross-Cultural Comparison | 1 | 1998 | 633 | 0.120 |
Why?
|
| Hospitalization | 2 | 2020 | 10789 | 0.120 |
Why?
|
| New Jersey | 2 | 2007 | 291 | 0.120 |
Why?
|
| Female | 28 | 2024 | 391246 | 0.120 |
Why?
|
| Middle Aged | 22 | 2024 | 220359 | 0.110 |
Why?
|
| Health Priorities | 1 | 2017 | 374 | 0.110 |
Why?
|
| Pacific Islands | 1 | 2013 | 52 | 0.110 |
Why?
|
| Health Care Costs | 2 | 2018 | 3258 | 0.110 |
Why?
|
| Administration, Oral | 1 | 2021 | 4035 | 0.110 |
Why?
|
| Piperazines | 1 | 2024 | 2525 | 0.110 |
Why?
|
| Australia | 1 | 2017 | 1290 | 0.110 |
Why?
|
| Philippines | 2 | 2014 | 91 | 0.110 |
Why?
|
| Chronic Disease | 5 | 2016 | 9288 | 0.110 |
Why?
|
| Pharmacists | 1 | 1995 | 259 | 0.110 |
Why?
|
| New York | 2 | 2007 | 875 | 0.110 |
Why?
|
| Health Maintenance Organizations | 2 | 2006 | 660 | 0.100 |
Why?
|
| Cross-Sectional Studies | 7 | 2021 | 25941 | 0.100 |
Why?
|
| Pharmaceutical Services | 1 | 1993 | 141 | 0.100 |
Why?
|
| Thiazolidinediones | 1 | 2015 | 465 | 0.100 |
Why?
|
| Anticonvulsants | 4 | 2000 | 1879 | 0.100 |
Why?
|
| Ambulatory Care | 2 | 2017 | 2782 | 0.100 |
Why?
|
| Canada | 1 | 2017 | 2126 | 0.100 |
Why?
|
| Asia | 1 | 2013 | 620 | 0.100 |
Why?
|
| Hypoglycemic Agents | 2 | 2015 | 3149 | 0.100 |
Why?
|
| Cohort Studies | 4 | 2022 | 41337 | 0.090 |
Why?
|
| Poverty | 3 | 2013 | 2695 | 0.090 |
Why?
|
| Interviews as Topic | 1 | 2018 | 2659 | 0.090 |
Why?
|
| Europe | 1 | 2017 | 3441 | 0.090 |
Why?
|
| Patient Discharge | 1 | 2003 | 3474 | 0.090 |
Why?
|
| China | 3 | 2023 | 2339 | 0.080 |
Why?
|
| Evaluation Studies as Topic | 1 | 2011 | 1628 | 0.080 |
Why?
|
| Reimbursement, Incentive | 1 | 2014 | 542 | 0.080 |
Why?
|
| Socioeconomic Factors | 5 | 2016 | 7805 | 0.080 |
Why?
|
| Hypertension | 2 | 2008 | 8595 | 0.080 |
Why?
|
| Quality Indicators, Health Care | 1 | 2018 | 1822 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2018 | 3530 | 0.070 |
Why?
|
| Massachusetts | 1 | 2020 | 8803 | 0.070 |
Why?
|
| Program Evaluation | 1 | 2016 | 2493 | 0.070 |
Why?
|
| Patient Care Team | 2 | 1995 | 2511 | 0.070 |
Why?
|
| Reproducibility of Results | 7 | 2013 | 20080 | 0.070 |
Why?
|
| Infant, Newborn | 4 | 2016 | 26179 | 0.070 |
Why?
|
| Observation | 1 | 2008 | 312 | 0.070 |
Why?
|
| Palliative Care | 1 | 2022 | 3607 | 0.070 |
Why?
|
| Confidence Intervals | 2 | 2010 | 2932 | 0.070 |
Why?
|
| Male | 21 | 2021 | 359718 | 0.070 |
Why?
|
| Retrospective Studies | 5 | 2022 | 80345 | 0.070 |
Why?
|
| Adult | 20 | 2018 | 220007 | 0.070 |
Why?
|
| Physical Fitness | 2 | 2000 | 732 | 0.060 |
Why?
|
| Health Care Surveys | 1 | 2013 | 2435 | 0.060 |
Why?
|
| Models, Statistical | 2 | 2011 | 5075 | 0.060 |
Why?
|
| Medicare Part D | 1 | 2010 | 354 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 5508 | 0.060 |
Why?
|
| Acute Disease | 1 | 2016 | 7268 | 0.060 |
Why?
|
| Infant | 4 | 2016 | 36053 | 0.060 |
Why?
|
| Neoplasm Staging | 3 | 2018 | 11152 | 0.060 |
Why?
|
| Health Care Reform | 1 | 2013 | 1245 | 0.060 |
Why?
|
| Child, Preschool | 4 | 2016 | 42056 | 0.060 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2018 | 3164 | 0.060 |
Why?
|
| Urban Health Services | 1 | 2005 | 177 | 0.060 |
Why?
|
| Insurance Claim Review | 1 | 2008 | 738 | 0.060 |
Why?
|
| Physician-Patient Relations | 1 | 1997 | 3242 | 0.060 |
Why?
|
| Adolescent | 10 | 2016 | 87809 | 0.060 |
Why?
|
| Half-Life | 1 | 2004 | 652 | 0.050 |
Why?
|
| International Classification of Diseases | 1 | 2008 | 894 | 0.050 |
Why?
|
| Psychometrics | 3 | 1999 | 3051 | 0.050 |
Why?
|
| Research Design | 3 | 2011 | 6180 | 0.050 |
Why?
|
| Longitudinal Studies | 3 | 2007 | 14494 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2013 | 12159 | 0.050 |
Why?
|
| Low Back Pain | 2 | 2000 | 979 | 0.050 |
Why?
|
| State Health Plans | 1 | 2003 | 219 | 0.050 |
Why?
|
| Community Health Centers | 1 | 2005 | 453 | 0.050 |
Why?
|
| Electronics | 1 | 2022 | 315 | 0.050 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2003 | 345 | 0.050 |
Why?
|
| Costs and Cost Analysis | 2 | 2018 | 1677 | 0.050 |
Why?
|
| Computer Communication Networks | 1 | 2022 | 294 | 0.050 |
Why?
|
| Sex Factors | 2 | 2013 | 10546 | 0.040 |
Why?
|
| Antihypertensive Agents | 2 | 2008 | 2061 | 0.040 |
Why?
|
| Penicillins | 1 | 2023 | 407 | 0.040 |
Why?
|
| Anti-Retroviral Agents | 1 | 2010 | 1779 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 39262 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2015 | 3426 | 0.040 |
Why?
|
| Cost Control | 1 | 2002 | 630 | 0.040 |
Why?
|
| Patient Compliance | 1 | 2010 | 2688 | 0.040 |
Why?
|
| Aged, 80 and over | 5 | 2008 | 58980 | 0.040 |
Why?
|
| Medication Errors | 1 | 2005 | 784 | 0.040 |
Why?
|
| Translations | 1 | 1998 | 81 | 0.040 |
Why?
|
| Activities of Daily Living | 2 | 1999 | 2417 | 0.040 |
Why?
|
| Drug Stability | 1 | 1999 | 290 | 0.040 |
Why?
|
| Metoprolol | 1 | 2018 | 92 | 0.040 |
Why?
|
| Logistic Models | 1 | 2013 | 13312 | 0.040 |
Why?
|
| Relief Work | 1 | 1999 | 128 | 0.040 |
Why?
|
| Tanzania | 2 | 1999 | 1383 | 0.040 |
Why?
|
| Respiratory Tract Infections | 1 | 2005 | 1007 | 0.040 |
Why?
|
| Guideline Adherence | 1 | 2006 | 2283 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 2 | 2023 | 7408 | 0.030 |
Why?
|
| Child | 4 | 2021 | 79799 | 0.030 |
Why?
|
| Population Surveillance | 2 | 2003 | 2608 | 0.030 |
Why?
|
| Exercise Tolerance | 1 | 2000 | 830 | 0.030 |
Why?
|
| Jordan | 1 | 2014 | 73 | 0.030 |
Why?
|
| Health Services | 1 | 2000 | 753 | 0.030 |
Why?
|
| Delayed Diagnosis | 1 | 2018 | 464 | 0.030 |
Why?
|
| Ghana | 1 | 2014 | 312 | 0.030 |
Why?
|
| Professional Practice | 1 | 1995 | 313 | 0.030 |
Why?
|
| Sampling Studies | 2 | 2008 | 613 | 0.030 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 1995 | 389 | 0.030 |
Why?
|
| Risk Factors | 3 | 2018 | 74333 | 0.030 |
Why?
|
| Taiwan | 1 | 2013 | 505 | 0.030 |
Why?
|
| International Cooperation | 1 | 1999 | 1433 | 0.030 |
Why?
|
| Hospitals, Public | 1 | 2013 | 201 | 0.020 |
Why?
|
| Forecasting | 1 | 2021 | 2931 | 0.020 |
Why?
|
| Kenya | 1 | 2014 | 749 | 0.020 |
Why?
|
| Pharmacies | 1 | 2013 | 164 | 0.020 |
Why?
|
| Incidental Findings | 1 | 2016 | 698 | 0.020 |
Why?
|
| Educational Status | 1 | 1999 | 2514 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2015 | 12289 | 0.020 |
Why?
|
| Urban Population | 1 | 1999 | 2022 | 0.020 |
Why?
|
| Heart Diseases | 1 | 2003 | 2809 | 0.020 |
Why?
|
| Private Sector | 1 | 2013 | 397 | 0.020 |
Why?
|
| Africa, Eastern | 1 | 2010 | 76 | 0.020 |
Why?
|
| Young Adult | 2 | 2016 | 58748 | 0.020 |
Why?
|
| Uganda | 1 | 2014 | 1324 | 0.020 |
Why?
|
| Family Characteristics | 1 | 2014 | 1001 | 0.020 |
Why?
|
| Incidence | 1 | 2007 | 21391 | 0.020 |
Why?
|
| Sample Size | 1 | 2011 | 840 | 0.020 |
Why?
|
| Predictive Value of Tests | 3 | 2018 | 15286 | 0.020 |
Why?
|
| Mammography | 1 | 2018 | 2427 | 0.020 |
Why?
|
| Seizures | 1 | 2000 | 2917 | 0.020 |
Why?
|
| Exercise | 2 | 2000 | 5787 | 0.020 |
Why?
|
| Research | 1 | 1995 | 1974 | 0.020 |
Why?
|
| Prescriptions | 1 | 2008 | 388 | 0.020 |
Why?
|
| Biopsy | 1 | 2018 | 6771 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2016 | 4902 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 1996 | 5201 | 0.020 |
Why?
|
| Mortality | 1 | 2016 | 2916 | 0.020 |
Why?
|
| Health Facilities | 1 | 2010 | 578 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 1995 | 6015 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 1997 | 3448 | 0.010 |
Why?
|
| Health Status Disparities | 1 | 2016 | 1829 | 0.010 |
Why?
|
| Mental Health | 1 | 1999 | 3213 | 0.010 |
Why?
|
| Prospective Studies | 3 | 2000 | 54306 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2010 | 2569 | 0.010 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 3202 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2016 | 10185 | 0.010 |
Why?
|
| HIV Infections | 1 | 2010 | 17165 | 0.010 |
Why?
|
| Time Factors | 2 | 2018 | 40139 | 0.010 |
Why?
|
| Exercise Test | 2 | 2000 | 2128 | 0.010 |
Why?
|
| Boston | 1 | 1995 | 9278 | 0.010 |
Why?
|
| Polypharmacy | 1 | 2005 | 307 | 0.010 |
Why?
|
| Income | 1 | 2010 | 1875 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2016 | 8022 | 0.010 |
Why?
|
| Calorimetry, Indirect | 1 | 2000 | 174 | 0.010 |
Why?
|
| Warfarin | 1 | 2008 | 1518 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2018 | 64981 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2005 | 2294 | 0.010 |
Why?
|
| Weight Gain | 1 | 2010 | 2347 | 0.010 |
Why?
|
| Age Distribution | 1 | 2005 | 2893 | 0.010 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2000 | 378 | 0.010 |
Why?
|
| Algorithms | 1 | 1999 | 13982 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2010 | 9716 | 0.010 |
Why?
|
| Arm | 1 | 2000 | 583 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2010 | 8556 | 0.010 |
Why?
|
| Leg | 1 | 2000 | 1091 | 0.010 |
Why?
|
| Linear Models | 1 | 2005 | 5877 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 2000 | 1843 | 0.010 |
Why?
|
| Morbidity | 1 | 1999 | 1765 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2008 | 4897 | 0.010 |
Why?
|
| Attitude to Health | 1 | 2000 | 2029 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2000 | 2315 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2015 | 15760 | 0.010 |
Why?
|
| Heart Rate | 1 | 2000 | 4180 | 0.000 |
Why?
|
| Prevalence | 1 | 2005 | 15686 | 0.000 |
Why?
|
| Practice Guidelines as Topic | 1 | 2005 | 7475 | 0.000 |
Why?
|
| Comorbidity | 1 | 2000 | 10553 | 0.000 |
Why?
|
| Prognosis | 1 | 2000 | 29661 | 0.000 |
Why?
|